Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1318)	12/2/1997 1:35:00 AM
From: james	Read Replies (2) \| Respond to of 4676

MZ, looks like very thing is well-covered in telomerase. . The difficulties for syn. comp. in this case: (1) assay setup, by the outlook, telomease functions in a huge complex , extremely hard to minic in vitro. (2). nucleu-penetration of compounds are seldom documented or measured, (3) What is a relavent mice model. Conventional xenograft tumors (C6, skov3 etc) probably won't tell you a thing. How do they opt. libraries. Boy oh boy, isip & geron etc are in some deep ssss here. Yeast is the bet. Anybody ahead on this? The good news is, if some one starts next year, & might still be able to catch up with these guys, nobody is goning anywhere soon as far as I can tell (which is not much ahead of my nose). To me this one is a discounted item. But an assay or model could sell some $$$$$$. good luck to TI